Effect of Addition of Aromatase Inhibitor to Ovarian Stimulation Therapy in IVF Treatment

• Status: Completed
• Trial end date: 2018-10-30
• Target enrollment: 0
• Participant gender: Female

Summary

This project seeks to determine whether estradiol suppression achieved with adjuvant treatment with an aromatase inhibitor improves end-follicular and midluteal phase parameters during IVF. 128 patients will be randomized to either placebo or active treatment.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Sven O. Skouby
• Collaborators: Copenhagen University Hospital, Denmark; Holbaek Sygehus; Hvidovre University Hospital; Region Capital Denmark; Rigshospitalet, Denmark; Skåne University Hospital; Zealand University Hospital
• Treatments: Aromatase Inhibitors; Letrozole

Criteria

INCLUSION CRITERIA

• Indication for IVF/ICSI treatment

• Eligible for IVF/ICSI treatment according to local criteria

• Regular cycles 21-35 days (both included)

• Age < 40

• AMH 8- 32 (both included)

• Written consent

EXCLUSION CRITERIA

• Any contraindication for IVF/ICSI treatment according to local criteria

• Previous stimulation for IVF/ICSI with < 4 oocytes obtained

• PCOS

• Undergoing IVF/ICSI for the purpose of fertility preservation

• Allergy towards study drug